Lyass O - Search Results

1

Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.

Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, Leibel SA. Zelefsky MJ, et al. Among authors: lyass o. J Clin Oncol. 1998 Oct;16(10):3380-5. doi: 10.1200/JCO.1998.16.10.3380. J Clin Oncol. 1998. PMID: 9779716

2

Time trends in organ position and volume in patients receiving prostate three-dimensional conformal radiotherapy.

Mechalakos JG, Mageras GS, Zelefsky MJ, Lyass O, van Herk M, Kooy HM, Leibel SA, Ling CC. Mechalakos JG, et al. Among authors: lyass o. Radiother Oncol. 2002 Mar;62(3):261-5. doi: 10.1016/s0167-8140(01)00466-2. Radiother Oncol. 2002. PMID: 12175556

3

Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy.

Zelefsky MJ, Crean D, Mageras GS, Lyass O, Happersett L, Ling CC, Leibel SA, Fuks Z, Bull S, Kooy HM, van Herk M, Kutcher GJ. Zelefsky MJ, et al. Among authors: lyass o. Radiother Oncol. 1999 Feb;50(2):225-34. doi: 10.1016/s0167-8140(99)00011-0. Radiother Oncol. 1999. PMID: 10368047

4

Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.

Lyass O, Hubert A, Gabizon AA. Lyass O, et al. Clin Cancer Res. 2001 Oct;7(10):3040-6. Clin Cancer Res. 2001. PMID: 11595693 Clinical Trial.

5

Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy.

Nisman B, Barak V, Hubert A, Kaduri L, Lyass O, Baras M, Peretz T. Nisman B, et al. Among authors: lyass o. Anticancer Res. 2003 Mar-Apr;23(2C):1939-42. Anticancer Res. 2003. PMID: 12820483

6

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Safra T, et al. Among authors: lyass o. Ann Oncol. 2000 Aug;11(8):1029-33. doi: 10.1023/a:1008365716693. Ann Oncol. 2000. PMID: 11038041 Free article.

7

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.

Hubert A, Lyass O, Pode D, Gabizon A. Hubert A, et al. Among authors: lyass o. Anticancer Drugs. 2000 Feb;11(2):123-7. doi: 10.1097/00001813-200002000-00009. Anticancer Drugs. 2000. PMID: 10789595 Clinical Trial.

8

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?

Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V. Nisman B, et al. Among authors: lyass o. Cancer. 1998 May 15;82(10):1850-9. doi: 10.1002/(sici)1097-0142(19980515)82:10<1850::aid-cncr6>3.0.co;2-r. Cancer. 1998. PMID: 9587116 Clinical Trial.

9

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.

Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A. Symon Z, et al. Among authors: lyass o. Cancer. 1999 Jul 1;86(1):72-8. Cancer. 1999. PMID: 10391566

10

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.

Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Lyass O, et al. Cancer. 2000 Sep 1;89(5):1037-47. doi: 10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z. Cancer. 2000. PMID: 10964334 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters